Tocilizumab Successfully Treating Refractory Hearing Impairment in a Patient With Cogan Syndrome : A Case Report and Review of the Literature
Cogan syndrome (CS) is a rare systemic vasculitis characterized primarily by nonsyphilitic interstitial keratitis and vestibular and auditory dysfunction. In this article, we report the case of a 31-year-old male diagnosed with CS for 1 year. He was admitted to the hospital with fever, dizziness, headache, tinnitus, and hearing loss. After being treated with glucocorticoids, cellular immunosuppressants, and infliximab therapy, his symptoms were greatly relieved except for hearing loss. Then, he attempted to use tocilizumab (TCZ) which was ultimately effective in controlling the auditory dysfunction. In addition, we found 4 cases of TCZ for CS through a literature review and compared them with our patient. Although glucocorticoids are still the first-line treatment for CS, TCZ therapy provides fresh hope for patients who have refractory hearing impairment with hormone resistance, or whose hormone dosages cannot be lowered to maintenance levels.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Ear, nose, & throat journal - (2024) vom: 17. März, Seite 1455613241237079 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Yan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological agents |
|---|
| Anmerkungen: |
Date Revised 18.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1177/01455613241237079 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36984436X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36984436X | ||
| 003 | DE-627 | ||
| 005 | 20240318235145.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240318s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/01455613241237079 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1335.xml |
| 035 | |a (DE-627)NLM36984436X | ||
| 035 | |a (NLM)38494750 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Yan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tocilizumab Successfully Treating Refractory Hearing Impairment in a Patient With Cogan Syndrome |b A Case Report and Review of the Literature |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Cogan syndrome (CS) is a rare systemic vasculitis characterized primarily by nonsyphilitic interstitial keratitis and vestibular and auditory dysfunction. In this article, we report the case of a 31-year-old male diagnosed with CS for 1 year. He was admitted to the hospital with fever, dizziness, headache, tinnitus, and hearing loss. After being treated with glucocorticoids, cellular immunosuppressants, and infliximab therapy, his symptoms were greatly relieved except for hearing loss. Then, he attempted to use tocilizumab (TCZ) which was ultimately effective in controlling the auditory dysfunction. In addition, we found 4 cases of TCZ for CS through a literature review and compared them with our patient. Although glucocorticoids are still the first-line treatment for CS, TCZ therapy provides fresh hope for patients who have refractory hearing impairment with hormone resistance, or whose hormone dosages cannot be lowered to maintenance levels | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cogan syndrome | |
| 650 | 4 | |a biological agents | |
| 650 | 4 | |a biological factors | |
| 650 | 4 | |a glucocorticoids | |
| 650 | 4 | |a infliximab | |
| 650 | 4 | |a tocilizumab | |
| 700 | 1 | |a Hu, Jiarui |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Dongze |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Tong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Jing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ear, nose, & throat journal |d 1984 |g (2024) vom: 17. März, Seite 1455613241237079 |w (DE-627)NLM000261459 |x 1942-7522 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:17 |g month:03 |g pages:1455613241237079 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/01455613241237079 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 17 |c 03 |h 1455613241237079 | ||